Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Coherus Oncology Inc (NASDAQ: CHRS) was $0.75 for the day, down -7.88% from the previous closing price of $0.81. In other words, the price has decreased by -$7.88 from its previous closing price. On the day, 1.42 million shares were traded. CHRS stock price reached its highest trading level at $0.788 during the session, while it also had its lowest trading level at $0.733.
Ratios:
Our analysis of CHRS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 173.02. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on August 16, 2024, Downgraded its rating to Neutral and sets its target price to $1.50 from $4 previously.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 23 ’25 when Wahlstrom Mats sold 99,988 shares for $0.74 per share. The transaction valued at 73,881 led to the insider holds 0 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 86509208 and an Enterprise Value of 301872992. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.44. Its current Enterprise Value per Revenue stands at 1.109 whereas that against EBITDA is -3.88.
Stock Price History:
The Beta on a monthly basis for CHRS is 0.87, which has changed by -0.48551726 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -11.04%, while the 200-Day Moving Average is calculated to be -28.22%.
Shares Statistics:
CHRS traded an average of 1.53M shares per day over the past three months and 1264620 shares per day over the past ten days. A total of 115.91M shares are outstanding, with a floating share count of 105.41M. Insiders hold about 9.07% of the company’s shares, while institutions hold 51.07% stake in the company. Shares short for CHRS as of 1749772800 were 31942421 with a Short Ratio of 20.83, compared to 1747267200 on 33116849. Therefore, it implies a Short% of Shares Outstanding of 31942421 and a Short% of Float of 28.65.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
